{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:36:46Z","timestamp":1771306606365,"version":"3.50.1"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Drug-induced proximal tubule (PT) injury remains a serious safety concern throughout drug development. Traditional in vitro 2-dimensional (2D) and preclinical in vivo models often fail to predict drug-related injuries presented in clinical trials. Various 3-dimensional (3D) microphysiological systems (MPSs) have been developed to mimic physiologically relevant properties, enabling them to be more predictive toward nephrotoxicity. To explore the capabilities of an MPS across species, we compared cytotoxicity in hRPTEC\/TERT1s and rat primary proximal tubular epithelial cells (rPPTECs) following exposure to zoledronic acid and ibandronate (62.5\u2013500\u2009\u00b5M), and antibiotic polymyxin B (PMB) (50 and 250\u2009\u00b5M, respectively). For comparison, we investigated cytotoxicity using 2D cultured hRPTEC\/TERT1s and rPPTECs following exposure to the same drugs, including overlapping concentrations, as their 3D counterparts. Regardless of the in vitro model, bisphosphonate-exposed rPPTECs exhibited cytotoxicity quicker than hRPTEC\/TERT1s. PMB was less sensitive toward nephrotoxicity in rPPTECs than hRPTEC\/TERT1s, demonstrating differences in species sensitivity within both 3D and 2D models. Generally, 2D cultured cells experienced faster drug-induced cytotoxicity compared to the MPSs, suggesting that MPSs can be advantageous for longer-term drug-exposure studies, if warranted. Furthermore, ibandronate-exposed hRPTEC\/TERT1s and rPPTECs produced higher levels of inflammatory and kidney injury biomarkers compared to zoledronic acid, indicating that ibandronate induces acute kidney injury, but also a potential protective response since ibandronate is less toxic than zoledronic acid. Our study suggests that the MPS model can be used for preclinical screening of compounds prior to animal studies and human clinical trials.<\/jats:p>","DOI":"10.1093\/toxsci\/kfad123","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T17:23:24Z","timestamp":1701969804000},"page":"86-100","source":"Crossref","is-referenced-by-count":5,"title":["Zoledronic acid and ibandronate-induced nephrotoxicity in 2D and 3D proximal tubule cells derived from human and rat"],"prefix":"10.1093","volume":"198","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7110-3187","authenticated-orcid":false,"given":"Leslie J","family":"Valencia","sequence":"first","affiliation":[{"name":"Investigative Toxicology, Department of Safety Assessment, Genentech Inc. , South San Francisco, California 94080, USA"},{"name":"Pathology, Department of Safety Assessment, Genentech Inc., South San Francisco, California 94080, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1088-6510","authenticated-orcid":false,"given":"Min","family":"Tseng","sequence":"additional","affiliation":[{"name":"Investigative Toxicology, Department of Safety Assessment, Genentech Inc. , South San Francisco, California 94080, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6226-4285","authenticated-orcid":false,"given":"Mei-Lan","family":"Chu","sequence":"additional","affiliation":[{"name":"Pathology, Department of Safety Assessment, Genentech Inc., South San Francisco, California 94080, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0218-7804","authenticated-orcid":false,"given":"Lanlan","family":"Yu","sequence":"additional","affiliation":[{"name":"Investigative Toxicology, Department of Safety Assessment, Genentech Inc. , South San Francisco, California 94080, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5153-1990","authenticated-orcid":false,"given":"Adeyemi O","family":"Adedeji","sequence":"additional","affiliation":[{"name":"Pathology, Department of Safety Assessment, Genentech Inc., South San Francisco, California 94080, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0862-6441","authenticated-orcid":false,"given":"Tomomi","family":"Kiyota","sequence":"additional","affiliation":[{"name":"Investigative Toxicology, Department of Safety Assessment, Genentech Inc. , South San Francisco, California 94080, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,12,6]]},"reference":[{"key":"2024040414022660500_kfad123-B1","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1681\/ASN.2015010060","article-title":"A quantitative approach to screen for nephrotoxic compounds in vitro","volume":"27","author":"Adler","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"2024040414022660500_kfad123-B2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2215\/CJN.12191213","article-title":"Biomarkers of AKI: a review of mechanistic relevance and potential therapeutic implications","volume":"10","author":"Alge","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"2024040414022660500_kfad123-B3","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1046\/j.1523-1755.2003.00750.x","article-title":"Chemokines and chemokine receptors are involved in the resolution or progression of renal disease","volume":"63","author":"Anders","year":"2003","journal-title":"Kidney Int."},{"key":"2024040414022660500_kfad123-B4","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.kint.2018.06.034","article-title":"Kidney-on-a-chip: untapped opportunities","volume":"94","author":"Ashammakhi","year":"2018","journal-title":"Kidney Int."},{"key":"2024040414022660500_kfad123-B5","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1128\/AAC.02587-12","article-title":"Polymyxin B induces apoptosis in kidney proximal tubular cells","volume":"57","author":"Azad","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"2024040414022660500_kfad123-B6","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1124\/dmd.118.082958","article-title":"Emerging kidney models to investigate metabolism, transport, and toxicity of drugs and xenobiotics","volume":"46","author":"Bajaj","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"2024040414022660500_kfad123-B7","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.semnephrol.2018.12.004","article-title":"Cellular and molecular mechanisms of kidney toxicity","volume":"39","author":"Barnett","year":"2019","journal-title":"Semin. Nephrol."},{"key":"2024040414022660500_kfad123-B8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.phrs.2015.04.016","article-title":"Nephrotoxicity of ibandronate and zoledronate in Wistar rats with normal renal function and after unilateral nephrectomy","volume":"99","author":"Bergner","year":"2015","journal-title":"Pharmacol. Res"},{"key":"2024040414022660500_kfad123-B0085712","first-page":"1","article-title":"VEGF: Potential therapy for renal regeneration","volume":"4","author":"Chade","year":"2012","journal-title":"."},{"key":"2024040414022660500_kfad123-B9","doi-asserted-by":"crossref","first-page":"695920","DOI":"10.3389\/fphar.2021.695920","article-title":"Kidney organoid and microphysiological kidney chip models to accelerate drug development and reduce animal testing","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Pharmacol."},{"key":"2024040414022660500_kfad123-B10","first-page":"475","article-title":"Adverse effects of bisphosphonates: current issues","volume":"5","author":"Diel","year":"2007","journal-title":"J. Support. Oncol."},{"key":"2024040414022660500_kfad123-B11","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"2024040414022660500_kfad123-B12","doi-asserted-by":"crossref","first-page":"R27","DOI":"10.1186\/cc3995","article-title":"Toxicity of polymyxins: a systematic review of the evidence from old and recent studies","volume":"10","author":"Falagas","year":"2006","journal-title":"Crit. Care"},{"key":"2024040414022660500_kfad123-B13","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1007\/s00198-022-06499-4","article-title":"Renal safety of zoledronic acid for osteoporosis in adults 75 years and older","volume":"33","author":"Fixen","year":"2022","journal-title":"Osteoporos. Int."},{"key":"2024040414022660500_kfad123-B14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12882-016-0348-x","article-title":"Relationship of clusterin with renal inflammation and fibrosis after the recovery phase of Ischemia-Reperfusion injury","volume":"17","author":"Guo","year":"2016","journal-title":"BMC Nephrol."},{"key":"2024040414022660500_kfad123-B15","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00467-021-05121-9","article-title":"Drug toxicity in the proximal tubule: new models, methods and mechanisms","volume":"37","author":"Hall","year":"2022","journal-title":"Pediatr. Nephrol."},{"key":"2024040414022660500_kfad123-B16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1046\/j.1523-1755.2002.00433.x","article-title":"Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury","volume":"62","author":"Han","year":"2002","journal-title":"Kidney Int."},{"key":"2024040414022660500_kfad123-B17","doi-asserted-by":"crossref","first-page":"14888","DOI":"10.1038\/s41598-020-71629-z","article-title":"Glomerular clusterin expression is increased in diabetic nephropathy and protects against oxidative stress-induced apoptosis in podocytes","volume":"10","author":"He","year":"2020","journal-title":"Sci. Rep."},{"key":"2024040414022660500_kfad123-B18","doi-asserted-by":"crossref","first-page":"34845","DOI":"10.1038\/srep34845","article-title":"Bioprinting of 3D convoluted renal proximal tubules on perfusable chips","volume":"6","author":"Homan","year":"2016","journal-title":"Sci. Rep."},{"key":"2024040414022660500_kfad123-B19","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1159\/000520999","article-title":"Zoledronic acid contraindications prevalence among hip-fractured patients aged 75 years or over hospitalized in an orthogeriatric unit","volume":"68","author":"Jalbert","year":"2022","journal-title":"Gerontology"},{"key":"2024040414022660500_kfad123-B20","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1039\/c3ib40049b","article-title":"Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment","volume":"5","author":"Jang","year":"2013","journal-title":"Integr. Biol. (Camb)"},{"key":"2024040414022660500_kfad123-B16469286","first-page":"F905","article-title":"Vascular endothelial growth factor is a survival factor for renal tubular epithelial cells","volume":"278","author":"Kanellis","year":"2000","journal-title":"."},{"key":"2024040414022660500_kfad123-B21","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1517\/14740338.2015.1088520","article-title":"The safety of polymyxin antibiotics","volume":"14","author":"Kelesidis","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"2024040414022660500_kfad123-B22","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41572-021-00284-z","article-title":"Acute kidney injury","volume":"7","author":"Kellum","year":"2021","journal-title":"Nat. Rev. Dis. Primers."},{"key":"2024040414022660500_kfad123-B23","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1681\/ASN.2020010009","article-title":"Transcriptomes of major proximal tubule cell culture models","volume":"32","author":"Khundmiri","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"2024040414022660500_kfad123-B24","doi-asserted-by":"crossref","first-page":"420601","DOI":"10.1155\/2013\/420601","article-title":"Viability reagent, PrestoBlue, in comparison with other available reagents, utilized in cytotoxicity and antimicrobial assays","volume":"2013","author":"Lall","year":"2013","journal-title":"Int. J. Microbiol."},{"key":"2024040414022660500_kfad123-B25","first-page":"1008","article-title":"Species similarities and differences in pharmacokinetics","volume":"23","author":"Lin","year":"1995","journal-title":"Drug Metab. Dispos."},{"key":"2024040414022660500_kfad123-B26","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1158\/1078-0432.CCR-16-3083","article-title":"Clinically relevant concentrations of anticancer drugs: a guide for nonclinical studies","volume":"23","author":"Liston","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"2024040414022660500_kfad123-B27","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.tiv.2008.01.006","article-title":"Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: Implications for renal safety","volume":"22","author":"L\u00fche","year":"2008","journal-title":"Toxicol. In Vitro"},{"key":"2024040414022660500_kfad123-B28","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/jbmr.2058","article-title":"Renal safety in patients treated with bisphosphonates for osteoporosis: a review","volume":"28","author":"Miller","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"2024040414022660500_kfad123-B64987591","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1159\/000106505","article-title":"Blockade of IP-10\/CXCR3 promotes progressive renal fibrosis","volume":"107","author":"Nakaya","year":"2007","journal-title":"Nephron. Exp. Nephrol."},{"key":"2024040414022660500_kfad123-B29","article-title":"Polymyxin acute kidney injury: dosing and other strategies to reduce toxicity","volume":"8","author":"Nation","year":"2019","journal-title":"Antibiotics (Basel, Switzerland)"},{"key":"2024040414022660500_kfad123-B30","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.2215\/CJN.02440314","article-title":"Handling of drugs, metabolites, and uremic toxins by kidney proximal tubule drug transporters","volume":"10","author":"Nigam","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"2024040414022660500_kfad123-B31","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2215\/CJN.02050309","article-title":"Renal vulnerability to drug toxicity","volume":"4","author":"Perazella","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"2024040414022660500_kfad123-B32","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ki.2008.356","article-title":"Bisphosphonate nephrotoxicity","volume":"74","author":"Perazella","year":"2008","journal-title":"Kidney Int."},{"key":"2024040414022660500_kfad123-B33","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.2215\/CJN.11290821","article-title":"Drug-induced acute kidney injury","volume":"17","author":"Perazella","year":"2022","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"2024040414022660500_kfad123-B34","doi-asserted-by":"crossref","first-page":"F1231","DOI":"10.1152\/ajprenal.00557.2012","article-title":"Tumor necrosis factor-\u03b1: regulation of renal function and blood pressure","volume":"304","author":"Ramseyer","year":"2013","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"2024040414022660500_kfad123-B35","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/jbmr.4235","article-title":"Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: a binational cohort analysis","volume":"36","author":"Robinson","year":"2021","journal-title":"J. Bone Miner. Res."},{"key":"2024040414022660500_kfad123-B36","doi-asserted-by":"crossref","first-page":"111174","DOI":"10.1016\/j.biopha.2020.111174","article-title":"Clusterin: always protecting. Synthesis, function and potential issues","volume":"134","author":"Rodr\u00edguez-Rivera","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"2024040414022660500_kfad123-B37","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1111\/bcp.14780","article-title":"Bisphosphonate nephropathy: a case series and review of the literature","volume":"87","author":"Roij van Zuijdewijn","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"2024040414022660500_kfad123-B38","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.cca.2010.12.030","article-title":"Increased total cytokeratin-18 serum and urine levels in chronic kidney disease","volume":"412","author":"Roth","year":"2011","journal-title":"Clin. Chim. Acta."},{"key":"2024040414022660500_kfad123-B39","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S8756-3282(99)00116-7","article-title":"Bisphosphonates: from the laboratory to the clinic and back again","volume":"25","author":"Russell","year":"1999","journal-title":"Bone"},{"key":"2024040414022660500_kfad123-B40","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.tcb.2022.08.005","article-title":"Cut loose TIMP-1: an emerging cytokine in inflammation","volume":"33","author":"Schoeps","year":"2022","journal-title":"Trends Cell Biol"},{"key":"2024040414022660500_kfad123-B41","doi-asserted-by":"crossref","first-page":"e87496","DOI":"10.1371\/journal.pone.0087496","article-title":"A bioartificial renal tubule device embedding human renal stem\/progenitor cells","volume":"9","author":"Sciancalepore","year":"2014","journal-title":"PLoS One."},{"key":"2024040414022660500_kfad123-B42","doi-asserted-by":"crossref","first-page":"223","DOI":"10.14573\/altex.1710181","article-title":"RPTEC\/TERT1 cells form highly differentiated tubules when cultured in a 3D matrix","volume":"35","author":"Secker","year":"2018","journal-title":"ALTEX"},{"key":"2024040414022660500_kfad123-B43","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/0091270002239824","article-title":"The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function","volume":"43","author":"Skerjanec","year":"2003","journal-title":"J. Clin. Pharmacol."},{"key":"2024040414022660500_kfad123-B44","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41581-018-0003-9","article-title":"Advances in predictive in vitro models of drug-induced nephrotoxicity","volume":"14","author":"Soo","year":"2018","journal-title":"Nat. Rev. Nephrol."},{"key":"2024040414022660500_kfad123-B45","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3389\/fimmu.2017.00405","article-title":"Interleukin-6 signaling pathway and its role in kidney disease: an update","volume":"8","author":"Su","year":"2017","journal-title":"Front. Immunol."},{"key":"2024040414022660500_kfad123-B46","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1146\/annurev.pharmtox.48.113006.094615","article-title":"Biomarkers of acute kidney injury","volume":"48","author":"Vaidya","year":"2008","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"2024040414022660500_kfad123-B47","doi-asserted-by":"crossref","first-page":"e0121861","DOI":"10.1371\/journal.pone.0121861","article-title":"Endocytotic uptake of zoledronic acid by tubular cells may explain its renal effects in cancer patients receiving high doses of the compound","volume":"10","author":"Verhulst","year":"2015","journal-title":"PLoS One."},{"key":"2024040414022660500_kfad123-B48","doi-asserted-by":"crossref","first-page":"44517","DOI":"10.1038\/srep44517","article-title":"Functional coupling of human microphysiology systems: Intestine, liver, kidney proximal tubule, blood-brain barrier and skeletal muscle","volume":"7","author":"Vernetti","year":"2017","journal-title":"Sci. Rep."},{"key":"2024040414022660500_kfad123-B49","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.kint.2016.06.011","article-title":"Development of a microphysiological model of human kidney proximal tubule function","volume":"90","author":"Weber","year":"2016","journal-title":"Kidney Int."},{"key":"2024040414022660500_kfad123-B50","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123673","article-title":"Human kidney on a chip assessment of polymyxin antibiotic nephrotoxicity","volume":"3","author":"Weber","year":"2018","journal-title":"JCI Insight."},{"key":"2024040414022660500_kfad123-B51","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4103\/0973-1482.63570","article-title":"Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review","volume":"6","author":"Weide","year":"2010","journal-title":"J. Cancer Res. Ther."},{"key":"2024040414022660500_kfad123-B52","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12938-020-0752-0","article-title":"Organ-on-a-chip: recent breakthroughs and future prospects","volume":"19","author":"Wu","year":"2020","journal-title":"Biomed. Eng. Online."},{"key":"2024040414022660500_kfad123-B53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vascn.2014.11.003","article-title":"Use of the viability reagent PrestoBlue in comparison with alamarBlue and MTT to assess the viability of human corneal epithelial cells","volume":"71","author":"Xu","year":"2015","journal-title":"J. Pharmacol. Toxicol. Methods."},{"key":"2024040414022660500_kfad123-B54","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1038\/jid.2012.204","article-title":"The endogenous protease inhibitor TIMP-1 mediates protection and recovery from cutaneous photodamage","volume":"132","author":"Yokose","year":"2012","journal-title":"J. Invest. Dermatol."},{"key":"2024040414022660500_kfad123-B55","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1007\/s00204-018-2192-1","article-title":"Polymyxin B causes DNA damage in HK-2 cells and mice","volume":"92","author":"Yun","year":"2018","journal-title":"Arch. Toxicol."},{"key":"2024040414022660500_kfad123-B56","article-title":"Drug-induced nephrotoxicity assessment in 3D cellular models","volume":"13","author":"Yu","year":"2021","journal-title":"Micromachines. (Basel)"},{"key":"2024040414022660500_kfad123-B57","doi-asserted-by":"crossref","first-page":"F568","DOI":"10.1152\/ajprenal.00399.2009","article-title":"Loss of clusterin expression worsens renal ischemia-reperfusion injury","volume":"298","author":"Zhou","year":"2010","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"2024040414022660500_kfad123-B58","doi-asserted-by":"crossref","first-page":"746208","DOI":"10.3389\/fphar.2021.746208","article-title":"Drug transporters in the kidney: Perspectives on species differences, disease status, and molecular docking","volume":"12","author":"Zou","year":"2021","journal-title":"Front. Pharmacol."}],"container-title":["Toxicological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/toxsci\/advance-article-pdf\/doi\/10.1093\/toxsci\/kfad123\/54586916\/kfad123.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/toxsci\/article-pdf\/198\/1\/86\/57160350\/kfad123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/toxsci\/article-pdf\/198\/1\/86\/57160350\/kfad123.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T14:05:33Z","timestamp":1712239533000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/toxsci\/article\/198\/1\/86\/7459915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,6]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12,6]]},"published-print":{"date-parts":[[2024,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/toxsci\/kfad123","relation":{},"ISSN":["1096-6080","1096-0929"],"issn-type":[{"value":"1096-6080","type":"print"},{"value":"1096-0929","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3,1]]},"published":{"date-parts":[[2023,12,6]]}}}